CVRx (Nasdaq:CVRX) shares were up this morning on second-quarter results that beat the consensus revenue forecast.
The Minneapolis-based neuromodulation technology developer posted losses of $11.1 million, or 54¢ per share, on sales of just over $5 million for the three months ended June 30, 2022, for a more than $6 million bottom-line gain despite remaining in the red on sales growth of 61.1%.
CVRx’s losses per share of 54¢ fell in line with expectations on Wall Street, while the company’s revenues came in more than 6.8% ahead of analysts’ projections.
“I am very pleased with what we were able to accomplish in the second quarter. The adoption of Barostim continues to accelerate as we execute on our strategy to expand our sales force and leverage marketing initiatives to increase awareness while at the same time working with existing customers to help more patients,” CVRx President and CEO Nadim Yared said in a news release. “We anticip…